Business
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced the results of a study in a humanized mouse model and its publication in the Journal of Antimicro
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity","length":281,"tagName":"p"}]},{"val":[{"type":"text","content":"Notable differences were observed between the microbiome of IBZ- and fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX","length":253,"tagName":"p"}]},{"val":[{"type":"text","content":"Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"IBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA ","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1119,"olType":false},{"type":"text","content":"STATEN ISLAND, N.Y., March 3, 2025 /CNW/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced the results of a study in a humanized mouse model and its publication in the Journal of Antimicrobial Agents and Chemotherapeutics entitled: "Microbiome impact of ibezapolstat and oth...